A Pharmacokinetic Study of JKB-122 Tablets Compared to Capsule

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

UNKNOWN

Clinical Phase

PHASE1

Total Enrollment

8 participants

Study Classification

INTERVENTIONAL

Study Start Date

2020-08-31

Study Completion Date

2020-12-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The purpose of this study is to compare the pharmacokinetics of JKB-122 tablets with JKB-122 capsules in healthy male subjects subjects.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Pharmacokinetics Of Jaktinib In Subjects With Hepatic Impairment And Normal Hepatic Function

NCT04993404

Hepatic Insufficiency Healthy Subjects

COMPLETED PHASE1

Investigate the Effect of Food on the Pharmacokinetics of JLP-1310 in Healthy Male Volunteers

NCT02449187

Diabetes Hyperlipidemia

COMPLETED PHASE1

A Study to Evaluate the Effect of Hepatic Impairment on the Pharmacokinetics of KP-001

NCT06619054

Healthy Adults Hepatic Impairment

COMPLETED PHASE1

A Study to Compare the Pharmacokinetics of YM150 Formulation-A and Formulation-B

NCT01125657

Healthy Volunteer Pharmacokinetics of YM150

COMPLETED PHASE1

A Phase I Dosing Study of IkT-148009.

NCT06641557

Healthy

COMPLETED PHASE1

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

This clinical study will be a randomized, open-label, multiple-dose, two-period, crossover study in healthy male subjects. After screening, subjects will be randomized to receive either JKB-122 tablet or JKB-122 capsule in a 1:1 ratio. There will be two dosing periods (Period 1 and Period 2). Subjects who receive JKB-122 capsule during Period 1 will receive JKB-122 tablet during Period 2 and vice versa. The 2 dosing periods will be separated by a washout period.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Autoimmune Hepatitis

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

CROSSOVER

Primary Study Purpose

TREATMENT

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Capsule

JKB-122 capsule on period 1 followed by JKB-122 Tablet on period 2

Group Type ACTIVE_COMPARATOR

JKB-122 in capsule or tablet form

Intervention Type DRUG

JKB-122 is a TLR4 antagonist and will be administrated in capsule or tablet form

Tablet

JKB-122 tablet on period 1 followed by JKB-122 capsule on period 2

Group Type ACTIVE_COMPARATOR

JKB-122 in capsule or tablet form

Intervention Type DRUG

JKB-122 is a TLR4 antagonist and will be administrated in capsule or tablet form

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

JKB-122 in capsule or tablet form

JKB-122 is a TLR4 antagonist and will be administrated in capsule or tablet form

Intervention Type DRUG

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

1. The subject has a body mass index (BMI) range of 18.5 and \< 25.0 kg/m2 and weighs at least 50 kg.
2. Agreement for subject and female partner of childbearing potential to use acceptable method of contraception
3. The subject provided written informed consent.

Exclusion Criteria

1. Any history or evidence of any clinically significant major disease or malignancy, as judged by the Investigator.
2. Any clinically significant abnormality following the Investigator's review of the physical examination, ECG and clinical study protocol-defined clinical laboratory tests.
3. Use of prescribed or non-prescribed drugs (including vitamins, natural and herbal remedies, e.g. St. John's Wort) in the 2 weeks prior to study drug administration.
4. Consumption of grapefruit, pomelo, citrus fruits, starfruit, pomegranate, papaya, mango, rambutan, kiwi fruit, dragon fruit or passion fruit and products containing these fruits in the 2 weeks prior to study drug administration.
5. Current smoker or history of smoking within 3 months before the Screening Visit.
6. History of drinking more than 21 units of alcohol per week within 3 months prior to the Screening Visit.
7. Any use of drugs-of-abuse within 3 months before the Screening Visit.
8. Any significant blood loss or donation of blood (250 ml within 2 months or 500 ml within 3 months) prior to study drug administration.
9. Positive serology test for hepatitis B surface antigen (HBsAg), hepatitis C virus antibodies (HCVAb) or human immunodeficiency virus.
10. Participation in any clinical study or administration of any investigational product within 1 month of study drug administration.
11. The subject has any other condition, which in the opinion of the Investigator precludes the subject's participation in the clinical study.

Minimum Eligible Age

20 Years

Maximum Eligible Age

45 Years

Eligible Sex

MALE

Accepts Healthy Volunteers

Yes